Sign-on Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Prescription Drug User Fee Act (PDUFA)

Requests to include measures to increase public awareness of clinical trials in the PDUFA reauthorization process

Coalition for Clinical Trials Awareness letter 04/07/17

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate

Access to Care

Support for legislation that would improve patients’ access to care

Joint letter to Congress 02/02/2017

Letter to House 02/06/2017

Letter to Senate 02/06/2017

Food and Drug Administration (FDA)

Support for FDA appointment nominees and initiatives to streamline the cancer drug approval process

Gottlieb support letter 04/04/2017

Gottlieb support letter 03/13/2017

Oncology Center for Excellence letter 06/06/2016

Califf support letter 02/19/2016

Institute for Clinical and Economic Review (ICER)

National Institutes of Health (NIH)

Patient Support

Promoting incorporation of more patient support in policymaking

Friends of the Cancer Policy Institute letter 01/31/2017

Regulation of Lab-Developed-Tests (LTDs)

Urging policymakers to include FDA involvement in the regulation of LDTs

Letter to House 04/01/16

Letter to Senate 04/01/2016

Letter to House 01/24/2017

Letter to Senate 01/24/2017


Supporting lung cancer drug reimbursement by insurance companies

Regence reimbursement policy letter 02/14/2017


Support for coverage for screening to promote early detection of lung cancer

Letter to CMS supporting screening